Viridian Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 24.8 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.81B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o...